7 hrs ago
Dr Lal PathLabs Seen Rising Above Key Resistance
Dr Lal PathLabs is a company whose share price has been moving upward.
An analyst says the stock recently moved above an important price level of Rs 1,900.
The stock is now staying above that level.
This level may act like a floor that supports the price.
The analyst believes the stock could rise to between Rs 2,140 and Rs 2,180.
Traders were advised to consider buying the stock.
A stop loss of Rs 1,870 was suggested to limit potential losses.
The stock’s RSI reading of 66 shows continued buying interest and positive momentum.
Dr Lal PathLabs has maintained an uptrend marked by higher highs and higher lows.
The stock broke above horizontal resistance at Rs 1,900 and is consolidating above it.
Rs 1,900 is identified as an important support zone for the stock.
Analyst Vishnu Kant Upadhyay recommended buying the stock with a target of Rs 2,140-2,180.
The suggested stop loss is Rs 1,870, while the RSI at 66 indicates positive momentum.
- Who
- Dr Lal PathLabs and Vishnu Kant Upadhyay, AVP of Research at Master Capital Services.
- What
- A short-term buy recommendation was issued for Dr Lal PathLabs, with a target of Rs 2,140-2,180 and a stop loss of Rs 1,870.
- Where
- When
- Why
- The recommendation was based on the stock’s uptrend, breakout above Rs 1,900, position above key moving averages, RSI of 66, and relative strength against the benchmark.
Key facts
- Stock
- Dr Lal PathLabs
- Recommendation
- Buy
- Target price
- Rs 2,140-2,180
- Stop loss
- Rs 1,870
- Breakout level
- Rs 1,900
- RSI
- 66
- Analyst
- Vishnu Kant Upadhyay, AVP of Research at Master Capital Services
Sources
Related news
Kotak Securities Expert Names Three Short-Term Stock Picks
Jigar Patel Recommends Castrol, HDFC Life and Gabriel Short-Term
Analysts Recommend BEML, Supreme Petrochem and Venky’s Stocks
Suzlon, Ola Electric and SAIL: Key Trading Levels
Analyst Flags Caution on SBI, Coal India; Favors HAL
SMIFS highlights largecap stocks amid prolonged market weakness
Stocks in Focus: Sterlite Tech, Nykaa, JSW Cement, Others
Dr Lal PathLabs to Acquire 70% Stake in SN Genelab
Preventive Health Checks Gain Ground Across India’s Diagnostic Industry
Stocks in Focus as Companies Report Deals, Results, Changes
